What is Phil?
Phil operates as a modern alternative to traditional pharmaceutical access, affordability, and distribution methods. By leveraging a software-driven approach, the company integrates digital stakeholder experiences, patient access services, market access tools, and flexible distribution models. This comprehensive strategy enables pharmaceutical manufacturers to ensure timely and affordable therapy access for patients, addressing critical gaps in the healthcare supply chain. The company's focus on digital integration and flexible distribution positions it as a key innovator in the health-tech space.
How much funding has Phil raised?
Phil has raised a total of $176.1M across 6 funding rounds:
Other Financing Round
$2.1M
Series A
$10M
Series B
$25M
Series C
$23M
Series D
$56M
Debt
$60M
Other Financing Round (2015): $2.1M with participation from Tom Williams, Forerunner Ventures, FJ Labs, Fabrice Grinda, Eniac Ventures, and Uncork Capital
Series A (2017): $10M led by Eniac Ventures, Softtech VC, Crosslink Capital, Transmedia Capital, Forerunner Ventures, Uncork Capital, and Silicon Valley Bank
Series B (2019): $25M supported by Uncork Capital, Tarsadia Hotels, GreatPoint Energy, and Crosslink Capital
Series C (2021): $23M, investors not publicly disclosed
Series D (2021): $56M backed by Warburg Pincus
Debt (2025): $60M with participation from K2 HealthVentures
Key Investors in Phil
K2 HealthVentures
K2 HealthVentures is an alternative investment firm specializing in flexible, long-term financing for life sciences and healthcare companies. Their deep domain knowledge and adaptive capital structure support companies through various growth stages.
Warburg Pincus
Warburg Pincus is a leading global private equity firm focused on growth investing. They partner with management teams to build sustainable businesses across diverse industries and geographies.
Uncork Capital
Uncork Capital is a seed-stage venture firm dedicated to supporting startups from their earliest stages. They provide critical assistance through the challenges of early growth, aiming to build lasting partnerships with innovative companies.
What's next for Phil?
With its recent major strategic investment and substantial overall capital, Phil is poised for significant expansion. The company is likely to focus on scaling its platform capabilities, enhancing its digital integration services, and broadening its reach within the pharmaceutical industry. Future strategic moves may include further technological advancements in patient support services, optimizing distribution networks, and forging new partnerships with manufacturers seeking to improve patient outcomes and streamline market access. The sustained investor confidence signals a strong belief in Phil's business model and its potential to disrupt traditional pharmaceutical logistics.
See full Phil company page
